These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 15610062)

  • 1. Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus.
    Croom KF; Plosker GL
    Drugs; 2005; 65(1):137-52. PubMed ID: 15610062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
    Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
    Arca M
    Drugs; 2007; 67 Suppl 1():43-54. PubMed ID: 17910520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.
    Colhoun HM; Thomason MJ; Mackness MI; Maton SM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Fuller JH;
    Diabet Med; 2002 Mar; 19(3):201-11. PubMed ID: 11918622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
    Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H;
    Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CARDS trial: diabetic patients dealt a winning hand.
    Armani A; Toth PP
    Curr Atheroscler Rep; 2006 Sep; 8(5):429-32. PubMed ID: 16901414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.
    Lea AP; McTavish D
    Drugs; 1997 May; 53(5):828-47. PubMed ID: 9129869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Fuller JH;
    Diabetologia; 2005 Dec; 48(12):2482-5. PubMed ID: 16284747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
    Thomason MJ; Colhoun HM; Livingstone SJ; Mackness MI; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Fuller JH;
    Diabet Med; 2004 Aug; 21(8):901-5. PubMed ID: 15270795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials.
    Hsue PY; Bittner VA; Betteridge J; Fayyad R; Laskey R; Wenger NK; Waters DD
    Am J Cardiol; 2015 Feb; 115(4):447-53. PubMed ID: 25637322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.
    Ramsey SD; Clarke LD; Roberts CS; Sullivan SD; Johnson SJ; Liu LZ
    Pharmacoeconomics; 2008; 26(4):329-39. PubMed ID: 18370567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
    Knopp RH; d'Emden M; Smilde JG; Pocock SJ
    Diabetes Care; 2006 Jul; 29(7):1478-85. PubMed ID: 16801565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
    Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
    Drugs; 2004; 64 Suppl 2():43-60. PubMed ID: 15765890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
    Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
    Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
    Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus.
    Riche DM; McClendon KS
    Am J Health Syst Pharm; 2007 Aug; 64(15):1603-10. PubMed ID: 17646562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).
    Raikou M; McGuire A; Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; Fuller JH;
    Diabetologia; 2007 Apr; 50(4):733-40. PubMed ID: 17265034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.